Dose-dependent augmentation of cardiac systolic function
with the selective cardiac myosin activator, omecamtiv
mecarbil: a fi rst-in-man study / The effects of the cardiac myosin activator, omecamtiv
mecarbil, on cardiac function in systolic heart failure:
a double-blind, placebo-controlled, crossover, dose-ranging
phase 2 trial